Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...

CAR-modified stem cell memory T cells show greater expansion and persistence than standard CAR T cells, enabling complete ...

The first clinical trial to test the tumour-fighting power of a stem-cell-like class of long-lived immune cells suggests that ...

A first-in-human trial has shown that CAR T cells enriched for stem cell–like memory properties can induce complete remissions in blood cancer patients without the usual chemotherapy preconditioning.

Poseida Therapeutics says the lead allogeneic chimeric antigen receptor T-cell (CAR-T) candidate it is co-developing with Roche through an up-to-$6.2 billion-plus collaboration will advance to Phase ...

An early-stage trial indicates that CAR-T therapy using T memory stem cells may enable certain blood cancer patients to avoid pre-treatment chemotherapy. The modified therapy achieved higher complete ...

Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it is properly activated. In many patients, however, this response is too weak ...

Research reveals why Alzheimer’s brain damage doesn’t always lead to dementia, highlighting the role of protective brain ...